Investment company Venrock Healthcare Capital Partners led a $120m Series B round in Artiva Biotherapeutics, an oncology-focused biopharmaceutical company, with participation from Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, Janus Henderson Investors, Logos Capital, RTW Investments, Surveyor Capital, Wellington Management Company, 5AM Ventures, RA Capital Management, and venBio Partners. "The quality and support of the investor groups participating in this financing further validates the promise of our manufacturing first strategy, the potential of our NK cell platform, and our goal to provide safe, effective, and truly off-the-shelf cell therapy treatments that are immediately accessible to cancer patients. I would also like to welcome Bong Koh to our board of directors and look forward to drawing upon his expertise as we continue to advance our clinical and other development activities," Fred Aslan, Artiva CEO.